Professor and Associate Dean of Research
Midwestern University
Disclosure(s): Doseme: Advisor/Consultant; other: Additional not relevant to this abstract. If more information is needed about unrelated relationships, I can provide it.
Marc H. Scheetz, PharmD, MSc, FCCP, FCP, FIDSA, attained a Doctorate of Pharmacy from Butler University, earned a Masters of Science in Clinical Investigation degree at Northwestern University, and completed his pharmacy practice residency and an infectious diseases fellowship at Northwestern Memorial Hospital. Dr. Scheetz is an Associate Dean of Research and Professor at Midwestern University College of Pharmacy and holds a joint appointment in the Department of Pharmacology, College of Graduate Studies. Dr. Scheetz is the Director of the Pharmacometric Center of Excellence at Midwestern University. He practices clinically as an infectious diseases pharmacist at Northwestern Memorial Hospital in downtown Chicago, IL.
Dr. Scheetz has authored over 220 original research manuscripts and review articles in the area of anti-infective pharmacokinetics and pharmacodynamics and is an Associate Editor at the International Journal of Antimicrobial Agents. He has served as a member of the pharmacokinetic and Gram-positive subcommittee for Antimicrobial Resistance Leadership Group (ARLG), as an appointed member to the United States Committee on Antimicrobial Susceptibility Testing (USCAST), and on multiple Clinical and Laboratory Standards Institute (CLSI) working groups. He was formerly a member of the FDA Antimicrobial Drugs Advisory Committee, the Anti-Infective Drugs Advisory Committee, and a Special Government Employee. His primary research interest lies in the interface of the pharmacokinetic/pharmacodynamic interaction (i.e. between antimicrobials, pathogens, and hosts). He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases and identifying optimal exposures against the backdrop of toxicity. In addition to clinical studies, his group studies toxicology with in vivo and in vitro models and has been continuously funded by the NIH since 2014.